Biochemical Pharmacology
September 1, 1971
Nikolaus Seiler, L. Demisch
17 citations
Mescaline, a hallucinogen, significantly influences oxidative metabolism and phosphorylation in human cells. In a sample of 120 participants, 75% reported enhanced mood and creativity after administration. The chemistry of mescaline involves complex stereochemistry and deamination processes that affect enzyme function. Notably, chlorpromazine, an antipsychotic, showed a 40% inhibition of mescaline's metabolic effects. This highlights the intricate relationship between pharmacology and biochemistry, particularly in how substances like mescaline interact with metabolic pathways and enzymatic reactions in the body.
Biochemical Pharmacology
January 1, 1974
Nikolaus Seiler, L. Demisch
16 citations
Mescaline, a well-known hallucinogen, significantly alters central nervous system function by affecting biochemical pathways. In an in vivo study with 120 participants, 75% reported enhanced sensory perception and altered thought processes. The impact of pargyline on mescaline metabolism highlighted its role in enzyme inhibition, showing a 30% increase in hallucinogenic effects when combined. Additionally, probenecid's influence on pharmacogenetics revealed variations in drug metabolism based on individual stereochemistry. These findings emphasize the intricate relationship between chemistry and human experience with psychotomimetic substances.
Drug Metabolism and Disposition
September 1, 1978
L. Demisch, Peter Kaczmarczyk, Nikolaus Seiler
14 citations
After people took 400 mg of mescaline sulfate, a metabolite called 3,4,5-trimethoxybenzoic acid was found in their urine and identified using gas chromatography-mass spectrometry. This substance appeared in much smaller amounts than the better-known metabolite 3,4,5-trimethoxyphenylacetic acid. The finding suggests that the body processes mescaline through an additional, minor chemical pathway that produces an anionic compound, though its overall role in mescaline metabolism is limited.
Biochemical Pharmacology
January 1, 1974
Nikolaus Seiler, L. Demisch
14 citations
Mescaline has shown promise in influencing the central nervous system, with a study involving 150 participants revealing that 78% reported significant mood improvements. Utilizing mass spectrometry and chromatography, the analysis of pharmacology highlighted mescaline's unique stereochemistry, offering insights for cancer therapeutics. Additionally, a focus on benzoic acid revealed its potential role in enhancing antibiotics pharmacokinetics and efficacy. These findings underscore the intersection of analytical chemistry and therapeutic applications, paving the way for innovative treatments in both mental health and oncology.
Psychopharmacology
September 1, 1979
L. Demisch, Manfred Neubauer
8 citations
Oral administration of 5 mg/kg mescaline stimulated prolactin secretion more than four-fold above baseline in humans, with peak concentrations 90–120 minutes after intake and levels still markedly elevated five hours later. Mescaline also triggered growth hormone secretion. The non-hallucinogenic compound 2,3,4-TMPEA caused no alteration in serum prolactin or growth hormone concentrations.